| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/17/2004 | US20040115190 Methods and agents modulating upa/upar activity |
| 06/17/2004 | US20040115174 treating cancer by administering an immunogenic composition capable of inducing active immunity against at least one angiogenesis-related antigen. |
| 06/17/2004 | CA2508539A1 Gp120 specific antigens and uses thereof |
| 06/17/2004 | CA2508302A1 Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
| 06/17/2004 | CA2507711A1 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 06/17/2004 | CA2507077A1 Methods and compositions for inducing apoptosis in cancer cells |
| 06/17/2004 | CA2505583A1 Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods |
| 06/17/2004 | CA2453387A1 Compositions and methods related to nitrotyrosine-containing compounds as antigenic agents |
| 06/16/2004 | EP1428887A1 Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| 06/16/2004 | EP1428880A1 Kidney-specific urate transporter and gene thereof |
| 06/16/2004 | EP1428879A1 Polynucleotide vaccine |
| 06/16/2004 | EP1428870A1 Reduction in the virulence of mycobacterium tuberculosis and protection against tuberculosis by means of phop gene inactivation |
| 06/16/2004 | EP1428537A1 Stabilized preparations containing antibody |
| 06/16/2004 | EP1428524A1 Pulmonary delivery of aerosolized medicaments |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427827A2 Synthetic hcv envelope proteins and their use for vaccination |
| 06/16/2004 | EP1427826A2 Hiv-gag codon-optimised dna vaccines |
| 06/16/2004 | EP1427817A1 Multiplication of viruses in a cell culture |
| 06/16/2004 | EP1427815A2 Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture |
| 06/16/2004 | EP1427813A2 Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| 06/16/2004 | EP1427806A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 06/16/2004 | EP1427756A1 Modified human growth hormone |
| 06/16/2004 | EP1427754A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 06/16/2004 | EP1427752A2 New hepatitis c virus genotype, and its use as prophylactic, therapeutic and diagnostic agent |
| 06/16/2004 | EP1427750A1 Modified transferrin fusion proteins |
| 06/16/2004 | EP1427462A1 Method for inducing selectively suppressed immune response |
| 06/16/2004 | EP1427444A2 West nile vaccine |
| 06/16/2004 | EP1427443A1 Vaccine using papilloma virus e proteins delivered by viral vector |
| 06/16/2004 | EP1427442A2 Glycoconjugate vaccines for use in immune-compromised populations |
| 06/16/2004 | EP1427441A2 Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 06/16/2004 | EP1427432A2 Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
| 06/16/2004 | EP1427426A2 Gpi-anchored cytokines |
| 06/16/2004 | EP1427420A1 Use of 4-pyridylmethylphthalazines for cancer treatment |
| 06/16/2004 | EP1427405A2 Inflammation-inhibiting compounds |
| 06/16/2004 | EP1427404A2 Treatment of glial tumors with glutamate antagonists |
| 06/16/2004 | EP1427403A2 Valproic acid and derivatives for the combination treatment of human cancers, tumor metastasis and minimal residual disease |
| 06/16/2004 | EP1427377A2 Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen |
| 06/16/2004 | EP1427349A2 Interleukin-12 as a veterinary vaccine adjuvant |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1152767B1 Method for producing anti-tumor th1 cells |
| 06/16/2004 | EP1147117B1 Immunological adjuvant compounds |
| 06/16/2004 | EP0789563B1 Hepatitis virus b and c vaccines |
| 06/16/2004 | EP0787003B1 Animal model system for the testing of drug candidates for the treatment of leukemia or hiv |
| 06/16/2004 | EP0692027B1 Expression of beta-2-microglobulin in pichia pastoris |
| 06/16/2004 | EP0667908B1 Soluble t-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases |
| 06/16/2004 | CN1505678A Lactic acid bacteria as agents for treating and preventing allergy |
| 06/16/2004 | CN1505528A Immunogen comprising ligand bound hiv envelpe protein |
| 06/16/2004 | CN1505527A Combination therapy using anti-angiogenic agents and tnfa |
| 06/16/2004 | CN1505526A Compositions and methods for wt1 specific immunotherapy |
| 06/16/2004 | CN1505525A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 06/16/2004 | CN1505522A Stimulation of thymus for vaccination development |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504482A Separation and purification process for acellular whooping cough antigen albumen |
| 06/16/2004 | CN1504476A Polynucleotide for identifying polypeptide OT3 and coding OT3 of tumor cell and uses thereof |
| 06/16/2004 | CN1504240A Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof |
| 06/16/2004 | CN1504200A Red-legged disease, curlworm disease ecotype, immunity and prevention and cure technique of eelworm |
| 06/16/2004 | CN1153591C Composite preparation for preventing and treating young animal's darrhea and its preparation process |
| 06/16/2004 | CN1153589C Treatment of infertility and enhancement of fertilization capacity in mammalian males |
| 06/16/2004 | CN1153567C Scale production method of forming microparticles |
| 06/16/2004 | CN1153510C Vaccination against coccidiosis in ovum |
| 06/16/2004 | CN1153509C Vaccination against coccidiosis in ovum |
| 06/15/2004 | US6750324 Agents and methods for treatment of diseases associated with amyloid deposits of a beta in the brain such as alzheimer's disease; entail administering agents that induce a beneficial immunogenic response against the amyloid deposit |
| 06/15/2004 | US6750323 Platelet activation protein |
| 06/15/2004 | US6750194 Administering to the subject a safe and effective amount of a vpac receptor agonist selected from the group consisting of ro 25-1553, and pacap-38 |
| 06/15/2004 | US6750056 Metal binding proteins and associated methods |
| 06/15/2004 | US6750034 Useful as therapeutic agents for cancer, skin disorders, neuropathic pain, inflammatory, or coagulation diathesis/thrombosis; may also be useful for laundry detergents and skin care products; derived from humans |
| 06/15/2004 | US6750026 To diagnose diseases relating to under- or over-expression of hfgan72 receptor ligands; for treatment of obesity, diabetes, anorexia nervosa, bulimia, cachexia, chronic renal failure, congestive heart failure |
| 06/15/2004 | US6749857 Recombinant dimeric envelope vaccine against flaviviral infection |
| 06/15/2004 | US6749856 Mucosal cytotoxic T lymphocyte responses |
| 06/15/2004 | US6749854 Use of OX-2 to inhibit fetal loss |
| 06/15/2004 | US6749845 Modulated release particles for lung delivery |
| 06/15/2004 | US6749831 Reducing adverse effects of endotoxin; administering antigens of at least two gram negative bacterial strains of e. coli, pseudomonas and/or bacteroides |
| 06/15/2004 | CA2159330C Inhibition of leukocyte adhesion |
| 06/15/2004 | CA2109256C Technetium or rhenium-binding bi-hapten derivatives, a process for their preparation, diagnostic and therapeutic application, and kits and immunological reagents containing same |
| 06/15/2004 | CA2049921C Allergenic proteins from ragweed and uses therefor |
| 06/10/2004 | WO2004048925A2 NaCT AS A TARGET FOR LIFESPAN EXPANSION AND WEIGHT REDUCTION |
| 06/10/2004 | WO2004048575A2 Streptococcus pneumoniae surface polypeptides |
| 06/10/2004 | WO2004048432A2 Preparation of polyphosphazene microspheres |
| 06/10/2004 | WO2004048431A2 Polyphosphazene immunocstimulants |
| 06/10/2004 | WO2004048404A2 Multiple variants of meningococcal protein nmb1870 |
| 06/10/2004 | WO2004048402A2 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 06/10/2004 | WO2004047862A1 Novel amine-based adjuvant |
| 06/10/2004 | WO2004047861A1 Vaccines against viruses with cationic substances as adjuvants |
| 06/10/2004 | WO2004047860A2 Cells not presenting antigen for suppressing pathological immune reactions |
| 06/10/2004 | WO2004047826A1 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance |
| 06/10/2004 | WO2004047805A1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 06/10/2004 | WO2004047794A2 An allergen dosage form |
| 06/10/2004 | WO2004047793A1 Pharmaceutical allergen product |
| 06/10/2004 | WO2004047778A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | WO2004047762A2 Methods for treating cancer using porimin as a target |
| 06/10/2004 | WO2004047761A2 Mbcats as modifiers of the beta-catenin pathway and methods of use |
| 06/10/2004 | WO2004047757A2 Diagnosing and treating hematopoietic cancers |
| 06/10/2004 | WO2004047740A2 Composition and method for treating lupus nephritis |
| 06/10/2004 | WO2004047735A2 Broad spectrum anti-viral therapeutics and prophylaxis |
| 06/10/2004 | WO2004047728A2 Compositions and methods for the treatment of immune related diseases |
| 06/10/2004 | WO2004047720A2 Methods of inhibiting angiogensis via modification of a lysyl oxidase |
| 06/10/2004 | WO2004034995A9 Methods and reagents for inducing immunity |
| 06/10/2004 | WO2004032959A3 Methods of treating and preventing neurological symptoms caused by avian reovirus and novel associated characteristics |
| 06/10/2004 | WO2004032865A3 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| 06/10/2004 | WO2004030696A8 Composition for vaccination |